pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

4.23USD
24 Oct 2014
Price Change (% chg)

$0.16 (+3.93%)
Prev Close
$4.07
Open
$4.10
Day's High
$4.27
Day's Low
$3.98
Volume
44,288
Avg. Vol
58,809
52-wk High
$5.45
52-wk Low
$2.28

PSDV.OQ

Chart for PSDV.OQ

About

pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. As of June 30, 2011, the Company is focused on the treatment of chronic eye diseases utilizing its cored technology systems, Durasert and BioSilicon. Its product candidate ILUVIEN, for the treatment of diabetic macular... (more)

Overall

Beta: 1.57
Market Cap (Mil.): $124.10
Shares Outstanding (Mil.): 29.34
Dividend: --
Yield (%): --

Financials

  PSDV.OQ Industry Sector
P/E (TTM): -- 154.10 34.06
EPS (TTM): -0.49 -- --
ROI: -79.75 -1.61 17.45
ROE: -118.06 -6.70 18.26
Search Stocks

Alimera, pSivida eye implant finally wins U.S. approval

- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

UPDATE 1-Alimera, pSivida eye implant finally wins U.S. approval

Sept 26 - Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

Alimera's eye implant Iluvien wins FDA approval

Sept 26 - The Food and Drug Administration has approved Alimera Sciences Inc's and pSivida Corp's vision-loss treatment Iluvien after three rejections.

26 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks